Hyperglycemia is a recognized risk factor for cardiovascular complications in diabetes. While hyperglycemia is known to cause microRNA dysregulation that contributes to cellular activation, whether it
Morbid obesity represents the most severe form of obesity and is associated with increased cardiometabolic risk, including type 2 diabetes and cardiovascular complications. Current diagnostic approach
Objective Although both clinical data and animal models suggest cardiovascular benefits following administration of Dipeptidyl Peptidase 4 (DPP-4) inhibitors, the underlying mechanisms remain unclear.
The ongoing pandemic of COVID-19 has entered a new phase. Despite the reduced pathogenicity of the currently prevalent Omicron variant of SARS-CoV-2, there is still a risk of severe illness and death.
